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ABSTRACT: Binding of a family of brominated benzotriazoles to
the catalytic subunit of human protein kinase CK2 (hCK2α) was
used as a model system to assess the contribution of halogen bonding
to protein−ligand interaction. CK2 is a constitutively active
pleiotropic serine/threonine protein kinase that belongs to the
CMGC group of eukaryotic protein kinases (EPKs). Due to the
addiction of some cancer cells, CK2 is an attractive and well-
characterized drug target. Halogenated benzotriazoles act as ATP-
competitive inhibitors with unexpectedly good selectivity for CK2
over other EPKs. We have characterized the interaction of
bromobenzotriazoles with hCK2α by X-ray crystallography, low-
volume differential scanning fluorimetry, and isothermal titration
calorimetry. Properties of free ligands in solution were additionally characterized by volumetric and RT-HPLC measurements.
Thermodynamic data indicate that the affinity increases with bromo substitution, with greater contributions from 5- and 6-
substituents than 4- and 7-substituents. Except for 4,7-disubstituted compounds, the bromobenzotriazoles adopt a canonical pose
with the triazole close to lysine 68, which precludes halogen bonding. More highly substituted benzotriazoles adopt many additional
noncanonical poses, presumably driven by a large hydrophobic contribution to binding. Some noncanonical ligand orientations allow
the formation of halogen bonds with the hinge region. Consistent with a predominantly hydrophobic interaction, the isobaric heat
capacity decreases upon ligand binding, the more so the higher the substitution.
1. INTRODUCTION
CK2, formerly designated as casein kinase II, is a pleiotropic
serine/threonine kinase found in all eukaryotes.1 The
holoenzyme is a heterotetramer, consisting of two catalytic
α- and/or α′-subunits and two regulatory β-subunits.2 Unlike
other kinases, in particular signaling cascade ones, CK2 is a
constitutively active enzyme. It phosphorylates substrates with
serine/threonine in regions enriched in acidic residues. The
enzyme particularly favors targets with an acid or a
phosphorylated serine residue at the +3 position relative to
the substrate S/T.1 CK2 belongs to (or according to some
classifications, is closely related to) CMGC kinases that in
addition to CK2 also comprise cyclin-dependent kinases
(CDKs), mitogen-activated protein kinase (MAPK), glycogen
synthase kinase (GSK), and cyclin-dependent kinase-like
kinases (CDK-like kinases).3
The physiological role of animal CK2 is understood at least
partially from the loss of function phenotypes in mice.3
Disruption of the CK2 β-subunit gene leads to a cell-
autonomous defect and early embryonic lethality, even though
the noncatalytic β-subunits are not required for CK2 activity.
The loss of either α- or α′-subunits leads to milder phenotypes,
presumably due to the overlapping roles of the two variants.
Among them, α seems to have a broader function than α′ since
α is required for embryonic development,4 whereas α′ appears
to be important only for spermatogenesis.5 Studies of
mammalian CK2 substrates have identified a wide variety of
proteins, including many targets involved in gene expression
and protein synthesis but also signaling. CK2 appears to have a
general antiapoptotic role.6 Thus, some cancer cells are more
susceptible to CK2 inhibition than nonmalignant cells.
Attempts to exploit this “CK2 addiction”7 are underway,
using the orally available inhibitor Silmitasertib (CX-
4945).8−10 Possible indications include gastric cancer,11
hematological malignancies,12,13 and cholangiocarcinoma.14
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From a structural biology perspective, CK2 kinases are well
characterized. The first structure was reported for a maize α-
subunit15 and was followed by the structure of the human
holoenzyme containing all four subunits.16 At present over 200
structures of CK2 enzymes with various inhibitors have been
deposited in the public Protein Data Bank (PDB) repository,
and many more are available in commercial databases. The
CK2α subunit has a typical eukaryotic protein kinase (EPK)
fold17 with a smaller N-terminal lobe consisting mostly of β-
strands and the functionally important C-helix and a larger C-
terminal lobe that is predominantly α-helical and harbors
catalytically relevant loops. The active site region contains the
typical elements for an EPK.18,19 Based on a large number of
crystal structures and homology to PKA, a model for catalysis
has been developed,19 involving two Mg2+ ions, Mg12+ and
Mg22+, that coordinate the β- and γ- and α- and γ-phosphates
of the ATP cosubstrate, respectively. Most catalytic residues
are contributed from the C-terminal lobe. An aspartate (D175)
from the DFG motif (DWG in hCK2α) coordinates Mg12+
and Mg22+. Another aspartate (D156), from the Y/HRD motif
(HRD in hCK2α), is thought to accept a proton from the
substrate during catalysis. An asparagine (N161) anchors
Mg22+. The N-terminal lobe of CK2α contributes a lysine
(K68) from the N-loop and a glutamate (E81) from the C-
helix. The lysine ε-amino group interacts with α- (and β-)
phosphates of the ATP cosubstrate and is positioned by a salt
bridge to the glutamate.
Several characteristic features distinguish CK2 from most
other EPKs (as reviewed in refs 17 and 20). As a constitutively
active kinase, CK2 is typically, although with some
exceptions,21 crystallized with the C-helix and activation loop
in the active conformation.20 The active form is secured
intramolecularly by an N-terminal segment that has been
described as the functional equivalent of cyclins activating
cyclin-dependent kinases.20 The hinge region between the N-
and C-terminal lobes adopts a unique conformation that has
been cited as the structural explanation for the CK2 specific
promiscuity to accept either ATP or GTP as the cosubstrate
for the phosphorylation reaction.22
Benzotriazoles and in particular their halogenated derivatives
have long attracted interest because of their pharmacological
properties. The best studied of these compounds is 4,5,6,7-
tetrabromobenzotriazole (TBBt), the ATP-competitive inhib-
itor of type I (i.e., binding to the kinase in the active
conformation).23 As the ATP pockets of EPKs in the active
conformation are very similar,18 TBBt could be expected to
inhibit a broad spectrum of kinases. Surprisingly, this is not the
case. After the initial demonstration of its inhibitory activity
against CK2 (and not CK1),24 it was soon shown to be highly
selective for CK2, inhibiting to a significant extent only CDK2
and GSK3β of the CMGC group and PHK (phosphorylase
kinase) of the CaMK family.25
Recently, much effort has gone into the design of bisubstrate
analogue CK2 inhibitors that are based on benzotriazole
scaffolds, often in the tetrabrominated form.26−29 Moreover,
there have been efforts to extend the benzotriazole skeleton on
the triazole side to better explore the full size of the purine-
binding cavity.30 A derivative of tetrabromobenzimidazole
(TBBi), SEL24-B849, which inhibits PIM and FLT3 kinases, is
under development as a potential drug for hematological
malignancies.31
The promising pharmacological profile of TBBt has
triggered our extensive investigations of the entire series of
halogenated and particularly brominated benzotriazoles.32−37
We have determined the inhibitory activity of all nine possible
isomers of bromobenzotriazole against hCK2α,32 as well as
their binding affinity to the enzyme (using several comple-
mentary biophysical methods).33−35 The studies demonstrated
that 4,5,6- and 5,6-bromobenzotriazoles are nearly as potent as
inhibitors of hCK2α as TBBt. In contrast, 5-, 4,5-, 4,6-, and
4,5,7-bromobenzotriazoles bind hCK2α with substantially
lower affinities, and 4,7- and 4-bromobenzotriazoles virtually
do not bind to the enzyme. We have also determined
physicochemical parameters of the free ligands in aqueous
solution, including solubility, pKa for the dissociation of the
triazole proton,32 and a large set of hydrophobicity descriptors,
including the recently proposed solute excess volume.36
Structural information on the binding mode of halogenated
benzotriazoles to CK2 is complex. Structures of TBBt bound
to the α-subunit of maize CK2 (mCK2α)38 and human
CDK2/cyclin A kinase39 have been reported. A structure of
hCK2α in complex with 3-(4,5,6,7-Br4-1H-benzotriazol-1-
yl)propan-1-ol, which can be considered a nonionizable
TBBt analogue, has also been determined.40 The structures
of mCK2α in complex with TBBi41 and pentabromoindazole42
that differ in the nitrogen configuration in the heterocyclic ring
are known. Structures of benzotriazole compounds with other
bromination patterns bound in the hCK2α pocket are to our
knowledge not available. However, the structures of 5,6-
bromobenzotriazole (5,6-Br2Bt) in complex with mCK2α
36
and of the chloro analogue of 5,6-Br2Bt (5,6-Cl2-1-b-D-
ribofuranosyl-benzimidazole, DRB) bound to hCK2α43 have
been published.
Several hundred halogenated ligands have already been
identified in publicly available protein kinase structures.44
Although they mainly bind to the ATP-binding site, their poses
are significantly different.39,41,44,45 For halogenated benzotria-
zoles and benzimidazoles, prior studies have indicated that the
binding mode is determined by a tug of war between a
hydrogen bond/salt bridge and halogen bonding.41 The
estimation of the free energy of a halogen bond in real
biological systems is still controversial since the introduction of
a halogen atom (Cl, Br, I) into a ligand molecule affects many
of its physicochemical properties, including hydrophobicity,
polarity, and pKa of nearby ionizable groups. Our recent
thermodynamic studies on binding of variously brominated
benzotriazoles to hCK2α have supported the concept of the
predominant contribution of electrostatic interactions and
ligand (de)solvation to the free energy of binding.33
Here, we present a set of crystal structures of eight
halogenated benzotriazoles in complex with a catalytic subunit
of human protein kinase CK2. One of the nine studied ligands,
4,5,7-Br3Bt, was not reliably detected in the hCK2α ATP-
binding pocket in the cocrystal. The structural analysis is
accompanied by thermal denaturation and calorimetric data
that show an increase of ligand affinity with bromo
substitution. The thermodynamic data also indicate a decrease
of isobaric heat capacity upon ligand binding, attributable to
the hydrophobic contribution to complex formation.
2. METHODS
2.1. Reagents. Brominated benzotriazoles were obtained
as described previously.33,46 The catalytic domain of human
protein kinase (hCK2α) was expressed and purified according
to the published procedure.33 Protein sample homogeneity was
confirmed by gel electrophoresis. The thermal profile of
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fluorescence-monitored protein stability was used prior to the
calorimetric experiment as a descriptor of the proper folding of
the enzyme.34
2.2. Crystallization. hCK2α was stored at −80 °C in
glycerol solution prior to use. Before crystallization, the protein
was dialyzed against buffer A (25 mM Tris-HCl pH 8.5, 0.5 M
NaCl, 5 mM β-mercaptoethanol). The protein sample was
then concentrated on VivaSpin 50000 MWCO to 4−8 mg/mL
and mixed with a 0.25 M solution of a ligand in DMSO in 1:24
molar ratio. Crystals were grown in sitting drops by the vapor
diffusion method. The 2 μL drops were set up manually using
the 1:1 mixture of protein−ligand complex solution and
crystallization buffer (0.1 M sodium HEPES/MOPS buffer pH
7.5, 20 mM sodium formate, 20 mM ammonium acetate, 20
mM sodium citrate tribasic dihydrate, 20 mM sodium
potassium tartrate tetrahydrate, 20 mM sodium oxamate,
20% poly(ethylene glycol) 550 monomethyl ester, 10%
poly(ethylene glycol) 20000). Crystals could be flash-
cryocooled without an additional cryoprotection step.
Diffraction data were collected at the P14 beamline of
EMBL/DESY (Hamburg, Germany), P11 beamline of DESY
(Hamburg, Germany), and MX 14.1 beamline of BESSY
(Berlin, Germany). Preliminary diffraction experiments were
also carried out at the XRD1 beamline of ELETTRA (Trieste,
Italy).
2.3. Structure Determination. The structures were
readily solved by molecular replacement with the help of the
MolRep program47 using the structure of the human
holoenzyme as a model (PDB code 3WAR48). Subsequently,
they were rebuilt with the help of ARP/wARP49 and refined
with the REFMAC program.50 In the cases of multiple not-
easily resolvable ligand poses, the position of the ligands was
confirmed using anomalous difference maps generated with the
phases obtained from the Fourier transformation of the hCK2α
structures with the ligands omitted. The ligand constraints
were generated with the PRODRG server.51 Since some of the
crystals showed signs of weakly broken symmetry and could
only be integrated with a unit cell two times larger than that
observed in the other data, the Rfree reflections were selected in
thin resolution shells. Data collection and refinement statistics
are summarized in Table 1. The refined models and the
corresponding structure factors were deposited in the PDB
with the accession codes stated in the table.
2.4. Surface Area Calculations. The solvent accessible
surface changes were estimated with the Yasara Structure
package (www.yasara.com). All low-mass molecules other than


















space group P42212 P42212 P42212 P42212 P42212 P42212 P42212 P42212
cell dimensions
a, b (Å) 128.5 128.8 129.3 128.0 128.3 127.2 129.0 127.4
c (Å) 61.1 60.9 60.7 61.1 61.2 60.9 61.1 61.0
wavelength (Å) 0.9794 0.9116 0.9794 0.9794 0.9116 0.9117 0.9116 0.9116
resolution (Å) 1.73 1.67 1.81 1.46 1.64 1.93 1.69 1.88
lowest shell (44.3−5.15) (36.5−4.98) (36.5−5.38) (44.2−4.36) (44.3−4.89) (36.2−5.72) (44.4−5.03) (45.0- 5.60)













































































no. reflections 53681 59111 46962 88427 62198 38226 57252 41198
refinement
Rwork 16.02 14.44 16.39 15.39 14.86 15.33 14.88 15.97
Rfree 18.73 17.26 18.45 17.27 17.76 18.86 17.13 18.70
no. atomsb 3728 4076 3643 4152 3795 3855 3995 3799
protein 3244 3435 3196 3517 3233 3299 3405 3283
ligand 10 30 33 33 33 11 36 65
other 474 610 414 597 529 545 554 452
bond lengths rmsd
(Å)
0.007 0.008 0.007 0.006 0.007 0.005 0.006 0.005
bond angles rmsd
(deg)
1.40 1.44 1.39 133 1.36 1.27 1.35 1.25
Ramachandran
allowed (%) 100 99.7 100 100 100 100 100 100
favored (%) 96.4 96.7 96.8 97.3 96.7 96.4 95.8 96.7
mol probity clash
score
2.2 3.9 3.8 3.1 2.5 2.3 3.8 3.6
PDB code 6TLW 6TLV 6TLU 6TLS 6TLR 6TLP 6TLO 6TLL
aLowest and highest shell in parentheses. bAlternative conformations counted separately.
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ligands placed at the hCK2α ATP-binding site were removed
prior to the calculations. The polar surface included all
nitrogen and oxygen atoms together with their associated
hydrogens, while the nonpolar one covered all remaining
atoms with the exception of bromines, which were treated
separately. The change of solvent accessible surface upon
complex formation (ΔASA) was calculated as the difference
between the surface of the complex and the sum of the surfaces
of the ligand and the free protein calculated for crystal
structures. The ΔASA values were estimated separately for
each alternative position of the ligand and/or enzyme
conformation and then averaged using occupancies as weights
with RMSE values assigned as their inaccuracies.
2.5. Low-Volume Differential Scanning Fluorimetry
(nanoDSF). The assay was carried out in 25 mM Tris-HCl
(pH 7.5, 0.5 M NaCl) buffer with the protein and ligands
concentration preserved constant at 2.5 and 25 μM,
respectively. The samples were loaded into nanoDSF grade
Standard Capillaries (NanoTemper Technologies) and ana-
lyzed using the Prometheus NT.48 nanoDSF device (Nano-
Temper Technologies). Thermal unfolding of the protein was
monitored using a linear thermal ramp (1 °C·min−1; 20−80
°C) with an excitation power of 30%. All numerical models
were globally fitted to the experimental data, assuming a two-
state cooperative transition at Tm, using the Marquardt
algorithm52 implemented in the Origin 2019 package (Origin-
Lab, Northampton, MA; www.originlab.com) according to the
following equations.
F T F T p T F T p T( ) ( ) ( ) ( ) (1 ( ))fold fold unf fold= · + · −
p T G T RT( ) 1/(1 exp( ( )/ ))fold = + Δ
G T H C T T
T S C T T






Δ = [Δ + Δ · − ]
− ·[Δ + Δ · ]
G T H S T0 ( ) T Tm m m m= Δ = Δ − Δ ·
where F(T) is the observed fluorescence signal, Ffold(T) and
Funf(T) are the low- and high-temperature linear asymptotes of
F(T); ΔG(T) is the free energy of unfolding at a given
temperature; Tm is the middle-point transition temperature;
ΔHTm and ΔSTm are the heat and entropy of the unfolding at
Tm (ΔG(Tm) = 0); and ΔCp is the heat capacity change upon
the protein unfolding.53
2.6. Isothermal Titration Calorimetry (ITC). ITC
measurements were carried out using the MicroCal iTC200
(Malvern) calorimeter. The hCK2α samples were diluted to
the required protein concentration with the 25 mM Tris-HCl
pH 8 buffer containing 0.5 M NaCl. Stock ligand solutions
were diluted with the appropriate DMSO volume prior to
mixing with the buffer to obtain the required ligand
concentration and a final DMSO content of 1%. Due to the
limited solubility of halogenated benzotriazoles, all titration
experiments were performed in the reverse mode, in which
buffered ligand solution was placed in the calorimetric cell and
titrated with the protein solution.35 The resulting thermograms
were preprocessed with the supplied MicroCal ITC-ORIGIN
Analysis Software, and the thermodynamic parameters were
further estimated at each temperature using previously
reported customized procedures54,55 reimplemented in the
Origin 2019 package (OriginLab, Northampton, MA; www.
originlab.com).
For the three strongest ligands, the titration experiments
were additionally performed using the NanoITC calorimeter
(TA Instruments). We have found that heats of binding (ΔH)
estimated using the two calorimeters differ significantly. To
deal with these discrepancies, we have studied the reference
reaction of 18-crown-6 with BaCl2 recommended by IUPAC
(Table S1).
The dissociation constant was close to the reference value
for both calorimeters, but the enthalpy for binding was
consistent with the IUPAC value only for the MicroCal iTC200,
while for the NanoITC it was underestimated by approx-
imately 12%. Interestingly, a similar trend was reported by
others for the titration of TRIS with HNO3.
56 The inspection
of the raw data, together with the technical specification and
hardware-specific baseline determination algorithms, clearly
suggests that the thermodynamic data from the MicroCal
iTC200 are more reliable. Only these data were analyzed
further, but for completeness we also report thermodynamic
parameters determined with a NanoITC calorimeter (Table
S2). In all experiments the maximum ligand concentration of
10 μM was used to minimize a possible contribution of the
secondary binding site.
2.7. Density Measurements. Partial molar volumes were
estimated with a density meter Anton Paar DMA 5000 M at
20, 25, and 30 °C from the concentration−density dependency
for compounds dissolved in 50 mM phosphate buffer (pH 11).
The experimental procedure and the data analysis method
were described previously.36,57,58 The partial molar volume at
25 °C (V2
0) and thermal volumetric expansivity of the solute
(α2
0 = ∂V2
0/∂T) were estimated globally from two
independent dilution series. The density of pure solvent (d0)
was extrapolated individually for each experimental condition
(i.e., temperature and buffer preparation). The change of d0
with temperature was further used to determine thermal
volumetric expansivity coefficient of the bulk buffer according
to the formula α0 = −(∂d0/∂T)/d0.
3. RESULTS
3.1. Structural Analysis of hCK2α−Bromobenzotria-
zole Complexes. To verify the binding mode of brominated
benzotriazoles to human CK2α, crystals of the enzyme in
complex with eight differently halogenated ligands were
obtained (covering all but one combination of benzyl ring
modifications) (Table 1). Cocrystallization with the ninth
compound (4,5,7-Br3Bt) was attempted, but the ligand was not
detected in the ATP-binding pocket of the enzyme. The
crystals belonged to the P42212 tetragonal space group and
contained a single molecule of the complex in the asymmetric
unit. Probably due to the crystallization conditions, Mg2+ ions
were absent from the active site of the kinase, with surprisingly
little effect on the protein conformation including residues
directly involved in the metal chelation. All complexes
presented in this work show the hallmarks of the active CK2
form (Figure S1). In particular, the C-helix (residues 74−89)
of the N-terminal lobe and the activation loop (residues 182−
190) are precisely in the expected positions. However, the
complex structures differ notably from the reference
conformation of the active kinase by the disorder of the P-
loop (glycine-rich loop, residues 45−49). In the presence of
the cosubstrate ATP, the P-loop wraps over the triphosphate
and is fairly ordered. In its absence, as in our structures, it lacks
the anchor and becomes disordered (Figure S1).
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All bound bromobenzotriazoles were located in the ATP-
binding pocket (Figure 1). The ligand-binding modes were
deduced from the composite omit maps and independently
confirmed by the analysis of the crystallographic anomalous
signal from the bromine atoms (Figure S3). In all eight
structures, we have detected the signal from the bromine atoms
Figure 1. Ligand-binding pocket of human CK2α in complex with eight bromobenzotriazole inhibitors. Protein−ligand contacts including
hydrogen bonds are indicated in gray and halogen interactions in yellow. The side chains of most hinge region residues and the main chains of R47,
K68, and D175 are omitted for clarity. Composite omit (gray, contoured at 1 rmsd) and F0 − Fc (red/green contoured at ±3 rmsd) maps are
shown for the ligand. The last two panels depict four poses observed for TBBt. With the exception of the compounds with 4,7-substitution, the
bromobenzotriazoles can adopt a canonical pose. In many cases, particularly for the highly substituted benzotriazoles, multiple poses are observed.
Figure 2. Binding poses of bromobenzotriazoles in the hCK2α ATP-binding pocket. For the canonical pose (A) hydrogen bonding or salt bridge
formation is chosen over halogen bonding, while for some noncanonical poses (B) halogen-bonding interactions are formed, at the expense of the
hydrogen bond or salt bridge.
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even if the data were collected away from the absorption edge.
In some cases, additional binding sites on the surface were
observed, including a previously defined site located at the
interface of α- and β-domains (Figure S2).43 Interestingly, a
signature of a weak secondary binding site was also recently
reported for several bromobenzotriazoles using a combination
of MST and ITC.35
The binding modes of bromobenzotriazoles in the hCK2α
ATP-binding pocket are best described by dividing them into
one “canonical” and several “noncanonical” ones. The
canonical binding mode is observed for 4-BrBt, 5-BrBt, 4,5-
Br2Bt, 4,6-Br2Bt, 5,6-Br2Bt, and 4,5,6-Br3Bt (Figure 2). The
benzotriazoles in this group, except for 5-BrBt and 4,5-Br2Bt,
bind in one predominant pose, similar for all of them.
Additional binding modes are also observed for 4,6-Br2Bt and
4,5,6-Br3Bt, but they are clearly weaker than the dominant one.
The binding mode of 5-BrBt in the crystal structure resembles
that of 5,6-bromobenzotriazole. However, the ligand is
observed in two alternative positions. The single 5-bromo
substituent is located more or less deep in the ATP-binding
pocket and corresponds to either the 5- or 6-bromo substituent
of 5,6-Br2Bt. The identity of the 5-BrBt is unambiguously
confirmed by the secondary binding site in which only one
ligand pose is observed. For 4,5-Br2Bt, one of the binding
modes is similar to the canonical one, and the second one is
180° rotated, so that the positions of the 5-bromo substituent
and the N8 nitrogen are roughly preserved but the ligand is
flipped.
The canonical binding pose of bromobenzotriazoles in the
hCK2α-binding pocket orients the triazole toward the active
site lysine (K68) and the phenyl ring toward the hinge region.
Depending on the charge states of the lysine and the ligand in
Table 2. Thermal Stability of hCK2α in Complex with Nine Bromobenzotriazole Compounds Determined with Fluorescence-
Monitored Thermal Denaturation (nanoDSF) at pH 7.5 and 8.033 and Literature Data for the Inhibitory Activity of the
Studied Ligands32
ligand Tm (°C) at pH 7.5 ΔTm (°C) at pH 7.5 ΔTm (°C) at pH 833 IC50 (μM) at pH 7.532
apo 45.19 ± 0.03 − − −
4-BrBt 45.92 ± 0.05 0.7 ± 0.1 0.5 ± 0.1 119 ± 10
5-BrBt 47.17 ± 0.02 2.0 ± 0.1 1.8 ± 0.1 26 ± 3
4,5-Br2Bt 49.55 ± 0.05 4.4 ± 0.1 3.5 ± 0.1 10.6 ± 0.9
4,6-Br2Bt 49.21 ± 0.04 4.0 ± 0.1 3.6 ± 0.1 10.0 ± 2.2
4,7-Br2Bt 47.15 ± 0.03 2.0 ± 0.1 0.9 ± 0.1 72 ± 11
5,6-Br2Bt 52.96 ± 0.05 7.8 ± 0.1 7.4 ± 0.1 0.56 ± 0.02
4,5,6-Br3Bt 53.84 ± 0.04 8.7 ± 0.1 8.4 ± 0.1 0.38 ± 0.02
4,5,7-Br3Bt 49.81 ± 0.07 4.6 ± 0.1 5.2 ± 0.1 5.8 ± 0.9
4,5,6,7-Br4Bt (TBBt) 55.11 ± 0.03 9.9 ± 0.1 9.0 ± 0.1 0.27 ± 0.07
Figure 3. Thermodynamics of the hCK2α−bromobenzotriazole interaction. (A) Thermal unfolding of hCK2α complexes was monitored by
nanoDSF at pH 7.5 and 8.0. ΔTm values indicate the difference of the unfolding temperature in the presence and absence of a ligand. The dashed
line shows the expectation for no pH dependence. The more highly substituted bromobenzotriazoles stabilize the protein more strongly, indicating
tighter binding. (B) Correlation of the free energies of binding (at 25 °C) with hCK2α stabilization. Thin lines represent 95% confidence bands for
the fitted line. (C) Entropy−enthalpy compensation with respect to temperature. The arrows mark the general trend in the temperature range from
15 to 35 °C. Entropic ΔS and enthalpic −ΔH contributions decrease and increase strongly with temperature, respectively. The two effects mostly
compensate for the free energy of binding ΔG = ΔH − TΔS. Figures S6 and S7 show detailed trends observed for the particular ligands. (D)
Correlation of the solute thermal expansivity with the partial molar volume of ligands.
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the pocket (highly brominated benzotriazoles are expected to
be acidic), this binding pose creates the possibility for a
hydrogen bond or a salt bridge with the side chain of K68. For
the benzotriazoles with 5- and/or 6-bromo substituents, there
is also a chance for the formation of one or two halogen bonds
with carbonyl oxygen atoms of the kinase hinge region as the
acceptors. Since the potential hydrogen (or salt bridge) and
halogen-bonding partners are typically too distant to each
other for both interaction types to occur simultaneously, a tug
of war between them is set up. Not unexpectedly, this
competition is resolved in favor of the hydrogen bond or salt
bridge formation, judging from the distances in the crystal
structures. In the cases where this is possible (for compounds
with the 4-bromo substituent), the halogen bond may instead
be formed with one of the conformers of R47 or N118. The
arginine is anchored in the P-loop region that in these cases
adopts at least two distinct conformations; the asparagine
belongs to the hinge region.
The noncanonically binding bromobenzotriazole group is
comprised of the compounds with both 4- and 7-bromo
substituents present (4,7-Br2Bt and TBBt). Ligands from this
group are pushed away from the pocket by the presence of the
substituent in the “lateral” position. As a result, the hydrogen
bond/salt bridge formation is more difficult, and the
interaction is sometimes lost in favor of a halogen bond or
optimized shape complementarity. The 4,7-Br2Bt ligand is
bound in one dominant and one weaker mode. TBBt in turn,
possibly due to its disclike shape, explores essentially the entire
pocket, in multiple and not clearly separable poses. In some of
the orientations, the benzotriazole is closer to the hinge region,
so that halogen bonds may be formed. However, the lack of
discrimination between different poses of this ligand in the
CK2α pocket suggests that the hydrophobic effect is the
dominant driver for its binding.
3.2. Stabilization of hCK2α by the Bromobenzotria-
zoles. Recent comprehensive thermodynamic33 and biochem-
ical studies32 allowed us to rank bromobenzotriazole ligands in
terms of their binding affinity to hCK2α. The results clearly
demonstrated that a balance of hydrophobic and electrostatic
interactions has predominant contribution to the binding
affinity.32−34 The structures of hCK2α complexes shown above
as well as the published values of IC50 (Table 2)
32 were
determined at pH 7.5, while the previous thermodynamic
studies were performed at pH 8.0.33,35 This prompted us to
measure the thermal stabilities of hCK2α and its complexes at
pH 7.5 by fluorescence-monitored thermal denaturation
(nanoDSF) (Table 2). The extent of ligand-induced hCK2α
stabilization was almost the same at both pH values (Figure
3A). It grew with the number of bromo substituents, with
larger contributions from the modifications in 5 and 6 than 4
and 7 positions. We have previously shown that the
dissociation constants determined for halogenated benzotria-
zoles, when converted according to the ATP concentration in
the assay, perfectly reconstruct experimental IC50 values.
33
Similarly, the ITC-derived binding affinities generally agreed
with the inhibitory activities determined for the same ligands32
(Figure S4).
3.3. Calorimetric Analysis of the Bromobenzotria-
zole−hCK2α Interaction. Thermodynamic parameters of the
benzotriazole hCK2α complex formation were measured on
the MicroCal iTC200 (Malvern). All ligands could be analyzed,
with the exception of two weakly binding ones (4,7-Br2Bt and
4-BrBt). As expected, the calorimetric data confirmed the
benzotriazoles with bromo substituents in the 5 and 6
positions (TBBt, 4,5,6-Br3Bt and 5,6-Br2Bt) as the strongest
ligands. Tighter-binding ligands (more negative ΔG values)
stabilized hCK2α more strongly (Figure 3B). The binding of
the three strongest ligands was additionally followed with a
NanoITC calorimeter (Table S2, Figures S5 and S6).
We observed the usual entropy−enthalpy compensation. For
all ligands, the free energies of binding (ΔG) were only weakly
temperature-dependent, despite the strong temperature
dependence of enthalpies (ΔH) and entropies (ΔS). At higher
temperatures, the enthalpic contribution for ligand binding
increased, while the entropic change became more unfavorable
(Figure 3C, Figures S6 and S7). The slope values of the
TΔS(ΔH) linear trend varied in the narrow range of (0.99 ±
0.03), clearly identifying that these two contributions
compensate for the free energy of binding (ΔG = ΔH − TΔS).
Entropy−enthalpy compensation was also observed for the
number of bromo substituents in the ligand series. At fixed
temperature, the binding enthalpy was less favorable for the
more substituted brominated compounds. However, this effect
was more than compensated by the increase in the entropic
contribution. The strong entropic component can be
interpreted as a signature of the hydrophobic effect: binding
of the ligand releases more water molecules involved in the
ligand solvation (and present in the ligand-binding cavity) into
bulk solvent and thus increases the conformational freedom of
these water molecules.
Table 3. Free Energy of Binding at 25 °C (ΔGbind) and Heat Capacity Changes (ΔCp,bind) Associated with Bromobenzotriazole
Interaction with hCK2α Determined at pH 8 with the Aid of Isothermal Titration Calorimetry (ITC)
ligand ΔGbind (kJ·mol−1) ΔCp,bind (kJ·mol−1·K−1) ΔASA (Å2) log P36 α20 (cm3·mol−1·K−1) V20 (cm3·mol−1) log(τ)37
4-BrBt 370 ± 2 1.72 0.30 ± 0.08 139.6 ± 0.3 −0.65
5-BrBt −34.4 ± 0.6 −0.28 ± 0.13 376 ± 5 1.73 0.14 ± 0.20 132.7 ± 0.8 −0.41
4,5-Br2Bt −34.9 ± 0.4 −0.43 ± 0.05 404 ± 3 2.34 0.36 ± 0.21 151.7 ± 0.9 −0.39
4,6-Br2Bt −34.5 ± 0.4 −0.44 ± 0.06 391 ± 6 2.37 0.41 ± 0.21 155.4 ± 0.9 −0.38
4,7-Br2Bt 419 ± 1 2.37 0.19 ± 0.25 149.8 ± 1.0 −0.55
5,6-Br2Bt −40.9 ± 0.3 −0.59 ± 0.07 395 ± 1 2.36 0.33 ± 0.14 150.0 ± 0.6 −0.30
4,5,6-Br3Bt −39.5 ± 0.4 −0.68 ± 0.06 428 ± 4 2.96 0.49 ± 0.24 156.0 ± 1.0 −0.20
4,5,7-Br3Bt −34.5 ± 0.4 −0.68 ± 0.07 2.98 0.55 ± 0.23 174.7 ± 0.9 −0.22
4,5,6,7-Br4Bt −39.6 ± 1.4 −0.97 ± 0.10 479 ± 24 3.58 0.72 ± 0.28 194.1 ± 1.1 −0.00
Pearson’s r with ΔCp,bind 0.933 0.941 0.930 − 0.983
(0.980)a (0.994)a 0.949b1/0.980b2 0.999b1/0.997b2
aPearson’s r with ΔCp,bind with values for ligands with fractional dissociation <0.95 (5-BrBt and 5,6-Br2Bt) excluded. bLigands were divided into
two groups: b1 the ones with both C5 and C6 positions brominated and b2 the remaining ones.
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Since the isobaric heat capacity of water solvating the
hydrophobic surfaces is greater than for bulk water (despite the
misleading description of this phenomenon as the “iceberg”
effect59,60), the binding of hydrophobic ligands should be
accompanied by a decrease in the isobaric heat capacity
(ΔCp,bind < 0). Indeed, binding of brominated benzotriazoles
was accompanied by negative ΔCp,bind values (Table 3). The
effect was more pronounced for highly substituted benzo-
triazole ligands than for less substituted ones. However, the
ΔCp,bind values did not follow the binding affinity. Instead, the
ligands could be clustered into three groups, each with a
different number of bromine atoms attached to the 5 and 6
position of the benzotriazole (Figure S8). All strong hCK2α
ligands (Kd ∼ 0.1 μM; ΔGbind ∼ −40 kJ·mol−1) were
substituted at both C5 and C6; their weakly binding analogues
(Kd ∼ 1 μM; ΔGbind ∼ −35 kJ·mol−1) carried a single bromine
at C5/C6, while those unsubstituted at C5/C6 virtually did
not bind hCK2α.
3.4. Partial Molar Volume and Apparent Thermal
Expansivity of Bromobenzotriazoles in Solution. Ac-
cording to the Lum, Chandler, and Weeks (LCW) theory, the
hydrophobic interactions scale for solutes of subnanometer
size with the volume of the molecule rather than its surface.61
We have recently proposed partial molar volume as the
extensive parameter to describe both the solute volume and the
solute-induced reorganization of the solvation shell.36,57,58,62,63
By analyzing density data at three temperatures (20, 25, and 30
°C), we could estimate the partial molar volume of the ligand
(V2
0) and the bulk solvent density (d0(T)). We could further
separate the thermal expansivity coefficient of the bulk solvent
(α0) and the apparent expansivity of the solute (α2
0). The
latter parameter is comprised mainly of the thermal expansion
effect of the hydration shell. The values of α0 fell within the
narrow range of (26.9 ± 1.3) × 10−5 K−1, which is close to the
literature data for water (25.72 × 10−5 K−1 at 25 °C).64 The
density estimated at 25 °C for independent buffer preparations
varied minutely in the range of 1.00399−1.00403 g·cm−3,
significantly exceeding the water density at 25 °C, 0.9970449 g·
cm−3.64 The volumetric data concerning solute (V2
0, α2
0) are
listed in Table 3. The solute thermal expansivity (α2
0),
together with the change of isobaric heat capacity upon ligand
binding (ΔCp,bind), has already been associated with the
properties of the solvation layer.65,66 Importantly, α2
0 is
proportional to the partial molar volume V2
0 (Figure 3D).
So, V2
0 may be another descriptor of hydrophobic interactions.
Consequently, the volume-normalized solute expansivity
coefficient (α = α2
0/V2
0) is almost the same for all studied
bromobenzotriazoles (232 ± 22 × 10−5 K−1). Importantly, this
value substantially exceeds the thermal expansivity coefficient
of the bulk buffer (α0 = 26.9 ± 1.3 × 10
−5 K−1), clearly
confirming that water organization changes with temperature
more near the solute surface than in the bulk.
4. DISCUSSION
4.1. Comparison of the Canonical Bromobenzotria-
zole hCK2α Complexes with Prior Structures. Benzo-
triazole and purine scaffolds are almost isostructural.
Compared to the purines in ATP or GTP,67−69 the canonically
bound benzotriazoles are located deeper in the pocket and
further away from the hinge region (Figure S9AB). For
benzotriazoles with bromo substituents in the 5 or 6 positions,
the displacement avoids a steric conflict with the hinge (V116).
Instead, one of the 5 or 6 halogen atoms adopts a position
similar to that of the N6 atom of adenine. In the case of
adenine, the exocyclic N6 amino group donates a hydrogen
bond to the carbonyl oxygen atom of E114. For 5- or 6-
substituted bromobenzotriazoles the σ-hole of the bromine
atom could mimic electron-accepting properties of the N6
amino group. However, in the canonical hCK2α bromobenzo-
triazole complex structures, the distances between the
backbone carbonyl oxygen atoms of E114 (and V116) from
the hinge region of hCK2α and the bromine atoms are longer
than the 3.4 Å sum of van der Waals radii of oxygen and
bromine.70 Therefore, their location in the crystal structure is
not indicative of halogen bonding. Instead the triazole part of
the ligands tends to occupy a position close to that of the ATP
α-phosphate oxygen atom and thus mimic its ionic interaction
with the K68 at the bottom of the pocket.
4.2. “Noncanonical” Bromobenzotriazole hCK2α
Complexes vs Prior Structures. TBBt and 4,7-Br2Bt are
bound less deeply in the pocket of hCK2α compared to the
canonical pose because the ligand would otherwise clash with
the pocket walls. As a result, at least the tetrabromobenzo-
triazole tends to overlap better with the inferred binding of the
ATP purine (Figure S9CD). The ligand not only binds in a
shallower manner but also comes closer to the hinge, at least in
some of the binding poses. This opens up the possibility of
halogen bonding with the main chain carbonyl oxygen atoms
of the hinge region. In this respect, the noncanonical binding
mode of the benzotriazoles is similar to the binding mode of
tetrabromobenzotriazole analogues with extra steric bulk on
the triazole side, which are also pushed closer to the hinge
region.30 It is instructive to compare the binding modes of
TBBt to human CK2α with previously observed ones. All
previous studies of TBBt complexes with maize CK2α38 and
human CDK239 and of a TBBt derivative with human CK2α′45
have reported a single ligand -binding pose. Interestingly,
structural alignment shows that the alternative poses observed
for TBBt in this work share the same space, with particularly
good overlap of the halogen atom locations. The orientation of
TBBt and its analogues in almost all complexes of CK2 with
bisubstrate inhibitors26−29 is also consistent with the poses
observed in our structure (Figure S10). The multiple TBBt
poses observed by us and others suggest that the precise
binding mode is not well-defined for this ligand. Thus, the
thermodynamic contribution associated with the burial of its
large hydrophobic surface in the nonpolar ATP-binding pocket
of the kinase may predominate over specific interactions. This
conclusion is in line with the review demonstrating that
hydrophobic contacts determine the binding affinity (inhib-
itory activity) of halogenated benzotriazoles and benzimida-
zoles to protein kinases.41 Moreover, the “noncanonical”
locations of TBBt display short contacts between bromine
atoms and carbonyl oxygen atoms of E114 and V116 (Figures
1 and 2, poses close to the hinge). This is in line with our
recent thermodynamic study of the four possible isomeric
forms of dibromo−dichlorobenzotriazole, of which 5,6-Br2-4,7-
Cl2Bt has the highest affinity to hCK2α.
37 This result suggests
that, at least in solution, the binding of perhalogenated
benzotriazoles might be accompanied by two halogen bonds
involving substituents in positions 5 and 6.
4.3. Hydrophobic Effect and the Decrease in the
Isobaric Heat Capacity. The affinity of bromobenzotriazoles
to hCK2α increases with the number of bromine atoms.
Halogen substitutions in the 5 and 6 positions have larger
effects than those in the 4 and 7 positions. Thermodynamic
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data point to the hydrophobic effect as an important
contributor to binding. The strong entropic component can
be attributed to the release of highly ordered water molecules
from the surfaces of the ligand and binding cavity. The most
widely accepted signature of hydrophobically driven inter-
action is a decrease in the isobaric heat capacity (ΔCp,bind <
0).71 Such a decrease is indeed observed in our experiments. In
macromolecular crystallography, it is generally believed that for
a large macromolecular surface the ΔCp,bind values are
proportional to the solvent accessible surface area (ΔASA)
that is buried in the binding event. We have tested several
parametrizations that correlate the reduction of polar and
nonpolar solvent accessible surfaces upon ligand binding
(ΔASA) with the heat capacity change associated with this
process,72−75 but none of them properly predicted exper-
imental values (Table S3, Figure S11A−D). Instead, we see a
more pronounced drop in the heat capacity for the more highly
substituted and therefore larger bromobenzotriazoles. The
ΔCp,bind value increases more strongly with the number of
bromo substituents than a surface (or volume) argument
suggests (Figure 4A). In the case of the number of bromo
substituents as the independent variable, the correlation can be
approximated by a linear relationship with no significant offset
from the origin (Figure 4B). There are several explanations of
this effect that are not mutually exclusive.
First, the ΔCp,bind correction may depend on the degree of
hydrophobicity. This factor may be similar to other measures
of hydrophobicity, such as the water−octanol partition
coefficient (log P)36,37 or the partial molar volume,36 even
though molecular explanations for the ΔCp,bind effect76,77 treat
hydrophobicity as a qualitative rather than a quantitative
property. Indeed, Spolar parametrization extended for bromine
(3.47 J·mol−1·K−1·Å−2) reliably predicts all experimental
ΔCp,bind values (Figure S11E). This clearly indicates that
hydrophobic contribution of Br is approximately 2.5-fold larger
than that estimated for hydrocarbons (1.34 J·mol−1·K−1·
Å−2).73 Second, electrostatic interactions with solvating water
molecules decrease the heat capacity of the charged
compounds.78 Upon binding events this will be reflected in
heat capacity changes less negative than for the neutral
counterparts. We have tested the dependence of ΔCp,bind on
the water octanol partition coefficient, log P (Figure 4C), and a
hydrophobicity measure based on HPLC retention times,
log(τ) (Figure 4D). Both dependencies can be described by
linear regression. Two ligands (5-BrBt and 5,6-Br2Bt) were not
consistent with the regression line relating ΔCp,bind values and
the commonly used in silico derived hydrophobicity indicators
(ΔASA, log P). Since a relevant fraction of these two ligands is
neutral at pH 8.0 (0.26 and 0.08, respectively),46 one may
assume that the contribution of particular electrostatic
interactions should be reflected in ΔCp,bind values. Finally,
the ΔCp,bind change could also be due to the changes in protein
conformation.
4.4. Entropic Balance and Conformational Change in
the Protein upon Ligand Binding. Following the idea of
Spolar and Record,79 the entropic change associated with
ligand binding can be broken down into three main entropic
components, the loss of rotational and translational degrees of
freedom ΔSrt, the hydrophobic effect ΔSHE, and the reminder
ΔSother. Due to the rigidity of the brominated benzotriazoles,
ΔSother is most likely attributable to changes in the protein
conformation and order. The other two contributions to
entropic change can be estimated with known formulas.
The entropy decrease resulting from the loss of rotational
and translational degrees of freedom can be calculated based
on the following equation.80 Please note that we have
neglected a minute correction (∼6 J·mol−1·K−1) that allows
for the difference between the temperature T of interest and
the reference temperature Tref for which the formula was
originally developed (m is the molecular mass of the ligand):
S R m57 J mol K 5 ln( Da )rt
1 1 1Δ = − · · − · ·− − −
The change in heat capacity ΔCp,bind predicts a proportional
entropy change that depends on the logarithm of temperature.
S C T1.35 ln( /386 K )pHE ,bind
1Δ = − ·Δ · −
From the experimental dependence of the total entropy
change on temperature, we can extrapolate the temperature Ts
where the total entropy change is 0 (Figure S6DF and Table
S4). At this temperature
S T S S T S0 ( ) ( )bind s rt HE s other= Δ = Δ + Δ + Δ
The ΔSother contribution can be directly calculated using this
expression (Table S4). Our data suggest that the ΔSother
contribution is relatively minor for TBBt, 4,5,6-Br3Bt, and
Figure 4. Heat capacity changes (ΔCp,bind) associated with the
hCK2α−bromobenzotriazole interaction. ΔCp,bind values were corre-
lated with (A) the change in the solvent accessible surface of the
ligand and the protein, (B) number of bromo substituents, (C)
calculated water−octanol partition coefficient log(P),36 (D) pre-
viously measured HPLC-derived hydrophobicity data, log(τ),37 and
(E, F) V0
2 and α, respectively. In (C) and (E) 5,6-Br2Bt was excluded
from the regression analysis. Note that the scale on the abscissa does
not start at 0. None of the relationships is therefore a proportion, but
the dependence of ΔCp,bind on the number of bromo substituents
comes close to such a relationship. Thin lines represent 95%
confidence bands for the fitted line.
The Journal of Physical Chemistry B pubs.acs.org/JPCB Article
https://dx.doi.org/10.1021/acs.jpcb.0c10264
J. Phys. Chem. B 2021, 125, 2491−2503
2499
5,6-Br2Bt but equals 100−200 J·mol−1·K−1 for the other
bromobenzotriazoles. According to Spolar and Record, the
ΔSother entropy change of ∼100 J·mol−1·K−1 is indicative for
par t i a l un fo ld ing o f 5−6 res idues . 7 9 Res idues
30VVEWGNQD37 of hCK2α are disordered in the complexes
with large ΔSother, but not in those with ΔSother close to zero
(Figure S12). This suggests that this region may be important
for the protein contribution to entropic change, but since the
structures include an almost 60 amino acid long disordered
region at the C-terminus of the kinase (not visible in the crystal
structures), this assignment remains speculative.
4.5. Grouping Brominated Benzotriazoles Based on
Thermodynamic Data. According to the heat capacity upon
ligand binding (ΔCp,bind) and partial molar volume (V20), the
bromobenzotriazoles cluster into groups that differ in the
substitution pattern (Figure 4E, according to the F-test, the
alternative model with no grouping must be rejected at p ∼
10−4; F(1,5) = 57). Such a tendency may be discerned also for
solute thermal expansivity (Figure 4F, according to the F-test,
the alternative model with no grouping must be rejected at p =
0.023; F(1,4) = 12.6). Taken together, the thermodynamic
data clearly show interplay between the direct hydrophobic
effect, roughly represented by the number of bromine atoms in
the molecule, and the halogen-induced changes of the ligand
electronic properties related to the apparent polarity of the
compound.
TΔS and ΔCp,bind are commonly used thermodynamic
descriptors of the hydrophobic contribution to ligand binding.
They cluster bromobenzotriazoles in the same groups (Figure
5A, according to the F-test, the alternative model with no
grouping must be rejected at p ∼ 10−4; F(2,3) = 600). Similar
trends have been reported for the IC50 values (Table 2).
32
Moreover, the same regularity is observed for entropy−
enthalpy compensation (Figure 5B, the alternative model
assuming one group of ligands must be rejected at p = 0.003;
F(1,4) = 43.7), for which two parallel lines of the 0.965 ±
0.026 slope indicate an almost perfect compensation among
the grouped ligands. Such compensation is commonly
observed for protein−ligand81 and protein−protein82 systems.
The distance between the lines (estimated to be 4.9 kJ·mol−1
from the intercept values) reflects the difference in the free
energy of protein−ligand interaction observed for strongly
(5,6-Br2Bt, 4,5,6-Br3Br, TBBt) and weakly (5-BrBt, 4,5-Br2Bt,
4,6-Br2Bt, 4,5,7-Br3Br) binding ligands (Table 3). The
systematic discrepancies strongly support the presence of two
competing mechanisms of bromobenzotriazole hCK2α bind-
ingone for high-affinity ligands, in which both 5 and 6
positions are brominated, and the other one for ligands in
which one of the two positions remains unsubstituted.
5. CONCLUSIONS
Ligand-binding poses of brominated benzotriazoles in the CK2
active site are dictated by three competing drivers. These are
salt bridge or hydrogen bond formation with K68, halogen
bond formation with the linker region, and the hydrophobic
effect. Salt bridge or hydrogen bond formation on the one
hand and halogen bonding on the other hand are largely
mutually exclusive because the hCK2α linker region and K68
are too far apart for both interactions to occur simultaneously.
Salt bridge formation typically wins over halogen bonding
unless the former is sterically disfavored (as in 4,7-substituted
benzotriazoles). The hydrophobic effect plays a dominant role
in bromobenzotriazole hCK2α binding. Its contribution is
evidenced by the strong entropic drive (caused by the release
of water molecules from the ligand surface into the bulk
solvent) and by the negative ΔCp,bind. For the most highly
brominated ligand (TBBt), the hydrophobic effect is so
dominant that the ligand explores almost the entire cavity, thus
forgoing in some poses the favorable interaction with K68.
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